A Phase 1 interventional study of Midazolam and Tepotinib in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-28.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study investigated the effect of tepotinib on the pharmacokinetics (PK) of the Cytochrome P450 (CYP) 3A substrate midazolam determined from concentrations of midazolam and its main metabolite 1-hydroxymidazolam in healthy participants.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single oral dose of 7.5 milligrams (mg) midazolam tablet on Day 1 of treatment period 1. The washout period between midazolam administrations in Period 1 and Period 2 was 12 days.
Drug: Midazolam
All participants who received 7.5 mg midazolam tablet in treatment period 1 received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 along with 7.5 mg midazolam tablet on Day 11 in treatment period 2.
Drug: Midazolam · Drug: Tepotinib
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam
AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam
AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Maximum Observed Plasma Concentration (Cmax) of Midazolam
Cmax was obtained directly from concentration versus time curve.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Time to Reach Maximum Plasma Concentration (Tmax) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)
Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Elimination Half Life (t1/2) of Midazolam and Midazolam Metabolite (1-Hydroxymidazolam)
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam Metabolite (1-Hydroxymidazolam)
AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam Metabolite (1-Hydroxymidazolam)
AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Maximum Observed Plasma Concentration (Cmax) of Midazolam Metabolite (1-Hydroxymidazolam)
Cmax was obtained directly from concentration versus time curve.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Metabolic Ratio of Midazolam and Midazolam Metabolite (1-hydroxymidazolam)
Metabolic ratio was calculated as AUC 0-infinity of midazolam divided by AUC 0-infinity of 1-hydroxymidazolam.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 43 hours post-dose on Day 1 of period 1 and Day 11 of Period 2
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death
Adverse event (AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs.
Time frame: Baseline (Day 1 of treatment period 1) up to the End of Trial visit (Day 20)
Number of Participants With Clinically Significant Changes in Laboratory Values
Number of participants with clinically significant changes in laboratory values were reported. Clinical significance was decided by the investigator. Laboratory investigation included hematology and urinalysis.
Time frame: From Screening up to the End of Trial visit (Day 20)
Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG)
Number of participants with clinically significant changes in 12-lead ECG were reported. Clinical significance was decided by the investigator. The 12-lead ECGs were recorded after the participants have rested for at least 5 minute in supine position.
Time frame: Day 1 (Treatment Period 1) up to the End of Trial visit (Day 20)
Number of Participants With Clinically Significant Changes in Vital Signs
Number of participants with clinically significant changes in vital signs were reported. Clinical significance was decided by Investigator. Vital signs included body temperature, blood pressure and pulse rate.
Time frame: Day 1 (Treatment Period 1) up to the End of Trial visit (Day 20)
| Milestone | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Started | 12 | 0 |
| Completed | 12 | 0 |
| Not completed | 0 | 0 |
| Milestone | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Started | 0 | 12 |
| Completed | 0 | 12 |
| Not completed | 0 | 0 |
AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.
| hour*picogram per milliliter (h*pg/mL) | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam | 107969 ± 42.0 | 109477 ± 46.5 |
AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).
| h*pg/mL | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam | 109285 ± 41.9 | 110550 ± 46.2 |
Cmax was obtained directly from concentration versus time curve.
| pg/mL | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Midazolam | 49172 ± 59.7 | 50954 ± 54.1 |
Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.
| Hours | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Midazolam | 0.500 (0.500 to 1.50) | 0.508 (0.483 to 2.00) |
| Midazolam Metabolite (1- Hydroxymidazolam) | 0.500 (0.500 to 2.00) | 0.508 (0.483 to 2.00) |
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
| Hours | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Midazolam | 5.52 ± 31.4 | 4.81 ± 41.2 |
| Midazolam Metabolite (1- Hydroxymidazolam) | 6.34 ± 29.8 | 6.90 ± 26.8 |
AUC0-t a Pharmacokinetic (PK) parameter was calculated according to the mixed log linear trapezoidal rule.
| h*pg/mL | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of Midazolam Metabolite (1-Hydroxymidazolam) | 30589 ± 23.8 | 32627 ± 25.1 |
AUC0-inf was calculated as AUC0-t plus (+) AUCextra. AUCextra represents the extrapolated part of AUC0-inf calculated by Clastpred/Lambda z, where Clastpred is the predicted plasma concentration at the last sampling time point, calculated from the log-linear regression line for Lambda z determination at which the measured plasma concentration is at or above Lower limit of quantification (LLOQ).
| h*pg/mL | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Midazolam Metabolite (1-Hydroxymidazolam) | 31269 ± 23.0 | 33372 ± 24.4 |
Cmax was obtained directly from concentration versus time curve.
| pg/mL | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Midazolam Metabolite (1-Hydroxymidazolam) | 14909 ± 60.4 | 15852 ± 34.7 |
Metabolic ratio was calculated as AUC 0-infinity of midazolam divided by AUC 0-infinity of 1-hydroxymidazolam.
| ratio | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Metabolic Ratio of Midazolam and Midazolam Metabolite (1-hydroxymidazolam) | 0.286 ± 37.2 | 0.302 ± 34.3 |
Adverse event (AE) was defined as any untoward medical occurrence in participants which does not necessarily have causal relationship with treatment. AE was any unfavorable and unintended sign (including abnormal laboratory finding), symptom/disease temporally associated with use of medicinal product, whether/not considered related to medicinal product. A serious adverse event (SAE) was AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Term TEAE is defined as AEs starting/worsening after first intake of the study drug. TEAEs included both serious TEAEs and non-serious TEAEs.
| Participants | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| TEAEs | 1 | 10 |
| Serious TEAEs | 0 | 0 |
| TEAEs Leading to Death | 0 | 0 |
Number of participants with clinically significant changes in laboratory values were reported. Clinical significance was decided by the investigator. Laboratory investigation included hematology and urinalysis.
| Participants | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Laboratory Values | 0 | 0 |
Number of participants with clinically significant changes in 12-lead ECG were reported. Clinical significance was decided by the investigator. The 12-lead ECGs were recorded after the participants have rested for at least 5 minute in supine position.
| Participants | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) | 0 | 0 |
Number of participants with clinically significant changes in vital signs were reported. Clinical significance was decided by Investigator. Vital signs included body temperature, blood pressure and pulse rate.
| Participants | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 |
Collected over Baseline (Day 1 of treatment period 1) up to the End of Trial visit (Day 20). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Midazolam (Reference Treatment) | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Tepotinib + Midazolam (Test Treatment) | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Event | Midazolam (Reference Treatment) | Tepotinib + Midazolam (Test Treatment) |
|---|---|---|
| HeadacheNervous system disorders | 0/12 | 5/12 |
| Abdominal pain upperGastrointestinal disorders | 0/12 | 4/12 |
| DiarrheaGastrointestinal disorders | 0/12 | 4/12 |
| Abdominal painGastrointestinal disorders | 0/12 | 2/12 |
| Abdominal discomfortGastrointestinal disorders | 0/12 | 1/12 |
| Abdominal pain lowerGastrointestinal disorders | 0/12 | 1/12 |
| Gingival bleedingGastrointestinal disorders | 0/12 | 1/12 |
| NauseaGastrointestinal disorders | 0/12 | 1/12 |
| Medical device site reactionGeneral disorders | 1/12 | 0/12 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 35 ± 7.5 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 0 |
| Male | 12 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Oct 2018, 2 months.
Results were first posted in Jul 2023, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midazolam
Merck KGaA, Darmstadt, Germany →